| Name | Title | Contact Details |
|---|
MetaWorks is a Medford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ninos Latinos Unidos is a Colton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Grapefruit offers Health & Wellness Solutions including telehealth, tele-psychiatry/therapy, and behavioral health services. Having worked with school districts across the country during the pandemic, Grapefruit understands the administrative burdens the schools faced during the pandemic. Grapefruit knows that a successful, comprehensive program should include access along the continuum of care — from health promotion and prevention, to treatment. With a comprehensive telemedicine program, schools have the ability to address both the physical and behavioral needs of each child. Guidance Counselors, school nurses and the school administration are not equipped or trained to handle the increased need for mental and behavioral health our youth is plagued with. Grapefruit recognizes the critical nature of providing these services to children and young adults, now more than ever.
A leader in benefits management since 1938, MedBen excels in finding ways to help employer groups save money on their health care coverage. Our extensive service portfolio includes third party administration, consumer-driven products and worksite wellness.
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.